{"ticker": {"uuid": "21297a09-aa9b-4ab4-b13f-c095f19876b9", "symbol": "PBYI", "name": "Puma Biotechnology Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] PUMA BIOTECHNOLOGY, INC. SEC Filing", "summary": "This article details a PUMA BIOTECHNOLOGY, INC. SEC Filing of Form 144, indicating a proposed sale of securities. The filing shows that 9,386 shares of common stock, valued at $77,554.64, are to be sold through Fidelity Brokerage Services LLC, originating from restricted stock ve", "url": "https://www.stocktitan.net/sec-filings/PBYI/144-puma-biotechnology-inc-sec-filing-d232b7e2cfcb.html", "source_name": "Stock Titan", "published_at": "2026-07-09T09:11:39", "published_display": "09 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Puma Biotechnology Inc For: 8 July By Investing.com", "summary": "This article reports on a Form 4 filing for Puma Biotechnology Inc. dated July 8. Form 4s disclose transactions by insiders, but the article does not provide specific details from the filing. It briefly mentions Puma Biotechnology Inc. (PBYI) and its current stock performance.", "url": "https://ca.investing.com/news/stock-market-news/form-4-puma-biotechnology-inc-for-8-july-93CH-4726292", "source_name": "Investing.com Canada", "published_at": "2026-07-09T07:10:19", "published_display": "09 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology\u2019s Douglas M. Hunt sells $69,904 in shares", "summary": "Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 8,460 shares of the company's stock for $69,904. This transaction took place as part of a pre-arranged plan, with the stock trading near its 52-week high after a significant gain. Despite thi", "url": "https://www.investing.com/news/insider-trading-news/puma-biotechnologys-douglas-m-hunt-sells-69904-in-shares-93CH-4782864", "source_name": "Investing.com", "published_at": "2026-07-09T07:10:19", "published_display": "09 Jul 2026 07:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma biotechnology CFO Maximo Nougues sells $77,556 in stock", "summary": "Maximo F. Nougues, CFO of Puma Biotechnology, Inc. (NASDAQ:PBYI), sold 9,386 shares of company stock for $77,556 on July 6, 2026. This transaction was part of a pre-established sell-to-cover program, leaving Nougues with 230,637 shares. The sale occurred while PBYI stock was near", "url": "https://www.investing.com/news/insider-trading-news/puma-biotechnology-cfo-maximo-nougues-sells-77556-in-stock-93CH-4782856", "source_name": "Investing.com", "published_at": "2026-07-09T07:10:19", "published_display": "09 Jul 2026 07:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 By Investing.com", "summary": "Alan Auerbach, President and CEO of Puma Biotechnology (NASDAQ:PBYI), sold 44,058 shares of company stock for $364,051 on July 6, 2026, under a pre-established trading plan. This sale occurred while the stock was near its 52-week high, having gained 126% in the past year, though ", "url": "https://ng.investing.com/news/stock-market-news/alan-auerbach-puma-biotechnology-president-and-ceo-sells-364051-93CH-2592089", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T01:30:00", "published_display": "09 Jul 2026 01:30", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PUMA Biotechnology (PBYI) officer Douglas Hunt sells 8,460 shares under 10b5-1 plan", "summary": "Douglas M. Hunt, an officer at PUMA Biotechnology (PBYI), reported an open-market sale of 8,460 shares of company stock at an average price of $8.263 per share. This transaction was conducted under a Rule 10b5-1(c) sell-to-cover plan established on December 14, 2020. Following th", "url": "https://www.stocktitan.net/sec-filings/PBYI/form-4-puma-biotechnology-inc-insider-trading-activity-a4829d1521b0.html", "source_name": "Stock Titan", "published_at": "2026-07-09T00:43:37", "published_display": "09 Jul 2026 00:43", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology (PBYI) CFO sells 9,386 shares in 10b5-1 trade", "summary": "Puma Biotechnology's CFO, Maximo F. Nougues, sold 9,386 shares of common stock on July 6, 2026, for $8.263 per share, totaling approximately $78,000. This transaction was conducted under a pre-arranged Rule 10b5-1(c) sell-to-cover plan established in December 2020. After the sale", "url": "https://www.stocktitan.net/sec-filings/PBYI/form-4-puma-biotechnology-inc-insider-trading-activity-9702a28e772a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T23:43:38", "published_display": "08 Jul 2026 23:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology (PBYI) CEO sells 44,058 shares under 10b5-1 plan", "summary": "Puma Biotechnology's President and CEO, Alan H. Auerbach, sold 44,058 shares of common stock at $8.263 per share on July 6, 2026. This transaction was conducted under a pre-established Rule 10b5-1(c) sell-to-cover program adopted in December 2020. Following the sale, Auerbach sti", "url": "https://www.stocktitan.net/sec-filings/PBYI/form-4-puma-biotechnology-inc-insider-trading-activity-8c9b981062db.html", "source_name": "Stock Titan", "published_at": "2026-07-08T00:43:38", "published_display": "08 Jul 2026 00:43", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PUMA BIOTECHNOLOGY, INC. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Puma Biotechnology, Inc. (PBYI), indicating a proposed sale of securities under Rule 144. The filing details the acquisition of 44,058 shares through restricted stock vesting on July 1, 2026, and their intended sale on July 6, 2026", "url": "https://www.stocktitan.net/sec-filings/PBYI/144-puma-biotechnology-inc-sec-filing-056ca4797df4.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:40:22", "published_display": "06 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PBYI - Puma Biotechnology Inc Latest SEC Filings", "summary": "This article provides comprehensive financial data and performance metrics for Puma Biotechnology Inc (PBYI), including its latest stock close, market capitalization, income, sales, and various ratios. It also details insider and institutional ownership, analyst recommendations, ", "url": "https://finviz.com/stock?t=PBYI&b=2&p=d&ty=lf&page=5", "source_name": "Finviz", "published_at": "2026-07-04T18:09:31", "published_display": "04 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Puma Biotechnology Inc \u2013 NASDAQ:PBYI", "summary": "The article provides a snapshot of Puma Biotechnology Inc. (NASDAQ: PBYI) on TradingView, focusing on its \"Price to sales forward\" metric. It indicates that the market was closed at the time of viewing, with no trades, and offers various data points like financials, news, and tec", "url": "https://www.tradingview.com/symbols/NASDAQ-PBYI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T13:40:43", "published_display": "04 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology highlights targeted cancer therapies as investors watch Nasdaq-listed PBYI", "summary": "Puma Biotechnology is a Nasdaq-listed biopharmaceutical company focusing on targeted oncology therapies, particularly for HER2-positive breast cancer. The company's strategy involves commercializing its approved drug while investing in pipeline development for additional indicati", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/puma-biotechnology-highlights-targeted-cancer-therapies-as-investors-watch/69679640", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T12:09:59", "published_display": "03 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology awards stock to four new employees", "summary": "Puma Biotechnology, Inc. announced the grant of 31,625 restricted stock unit awards to four new non-executive employees. These awards are an inducement for new hires and will vest over a three-year period, with the first portion vesting on July 1, 2026, and subsequent portions ev", "url": "https://www.stocktitan.net/news/PBYI/puma-biotechnology-reports-inducement-awards-under-nasdaq-listing-62tusnize1gg.html", "source_name": "Stock Titan", "published_at": "2026-07-03T07:10:09", "published_display": "03 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026", "summary": "Puma Biotechnology (NASDAQ: PBYI) announced inducement restricted stock unit awards covering 31,625 shares to four new non-executive employees, approved by its Compensation Committee on July 1, 2026. These awards, granted under the company's 2017 plan, vest over three years, with", "url": "https://www.biospace.com/press-releases/puma-biotechnology-reports-inducement-awards-under-nasdaq-listing-rule-5635c4-july-2-2026", "source_name": "BioSpace", "published_at": "2026-07-03T04:09:06", "published_display": "03 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PBYI News | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFBLUFNLOF9wV3hhSGtaQ3QzeDllNEZpQlVOV29QZk1qX3FleGRmTy1UNXlvVnpWRDJBWnZvTlNmWlo5a1JjcVFjdk5BelhadGo4ZDJsZFJJVXpwNGc?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:02+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNOXEyZVlzMUpOenRqNVF2Tm8tdnJSa2luenExck1VM21XSnh0NHVSVFI0VDc1ejRVWnZqS0ZVMjNHNmFvT1JhNEoyX0lqMkVyUFMwTWJUWmV3ZlI4SFE5OFFjYVdvWUo0c19DNVRYYks2UW1PTFEzWGlaMW8yWlN3LU5oZ3JZaEZMVDk4TWJreTlIUWZzdng2cg?oc=5", "source_name": "Market source", "published_at": "2026-07-02T21:03:00+00:00", "published_display": "02 Jul 2026 21:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Growth Benchmark", "summary": "Puma Biotechnology, Inc. (NasdaqGS:PBYI), a biopharmaceutical company focusing on cancer care, has been added to the Russell Small Cap Comp Growth Benchmark, as well as several other Russell Growth benchmarks on June 29, 2026. This news follows previous announcements earlier in t", "url": "https://www.marketscreener.com/news/puma-biotechnology-inc-nasdaqgs-pbyi-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd8efe22", "source_name": "marketscreener.com", "published_at": "2026-06-30T16:12:19", "published_display": "30 Jun 2026 16:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 2500 Growth Benchmark", "summary": "Puma Biotechnology, Inc. (NasdaqGS: PBYI) has been added to the Russell 2500 Growth Benchmark, as well as several other Russell indices including the Russell Small Cap Comp Growth Benchmark, Russell 2000 Growth Benchmark, and Russell 3000E Growth Benchmark. This news comes shortl", "url": "https://www.marketscreener.com/news/puma-biotechnology-inc-nasdaqgs-pbyi-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f326", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:41:16", "published_display": "29 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 3000E Growth Benchmark", "summary": "Puma Biotechnology, Inc. (PBYI) has been added to the Russell 3000E Growth Benchmark. This news follows a previous announcement that the company was also added to the Russell 2000 Growth Benchmark on the same day. Puma Biotechnology specializes in developing and commercializing p", "url": "https://www.marketscreener.com/news/puma-biotechnology-inc-nasdaqgs-pbyi-added-to-russell-3000e-growth-benchmark-ce7f5fdeda88f720", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:06:00", "published_display": "29 Jun 2026 12:06", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Puma Biotechnology Inc \u2013 BOATS:PBYI", "summary": "This article provides a financial snippet for Puma Biotechnology Inc (PBYI), specifically its enterprise value to revenue forward metric. The content highlights the stock's market status as closed with no recent trades and is presented within the TradingView platform.", "url": "https://www.tradingview.com/symbols/BOATS-PBYI/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:10:24", "published_display": "29 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PBYI Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Puma Biotechnology Inc (PBYI) stock, including analyst price targets and historical performance data. One analyst projects a maximum and minimum price target of $5.00 for PBYI. The stock has shown significant increases over the past year, and ", "url": "https://www.tradingview.com/symbols/NASDAQ-PBYI/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T15:39:45", "published_display": "28 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Puma Biotechnology Inc \u2013 NASDAQ:PBYI", "summary": "This article provides financial information for Puma Biotechnology Inc (NASDAQ: PBYI), specifically its price-to-book forward ratio. It highlights that the market was closed at the time of access and contains no active trades or specific current values. The content appears to be ", "url": "https://www.tradingview.com/symbols/NASDAQ-PBYI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:09:46", "published_display": "28 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Puma Biotechnology Inc \u2013 BOATS:PBYI", "summary": "This article provides financial information for Puma Biotechnology Inc (PBYI), specifically its price to sales forward metric. The content indicates that the market is currently closed with no trades. It also links to various TradingView features and legal information.", "url": "https://www.tradingview.com/symbols/BOATS-PBYI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:40:37", "published_display": "27 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Puma Biotechnology Inc \u2013 BOATS:PBYI", "summary": "This article displays an enterprise value to EBITDA forward metric for Puma Biotechnology Inc (PBYI), as presented by Blue Ocean Alternative Trade System (BOATS) on TradingView. The page primarily showcases financial data with no specific values or analytical commentary provided ", "url": "https://www.tradingview.com/symbols/BOATS-PBYI/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:09:47", "published_display": "27 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. Actuals & Estimates (NASDAQ:PBYI)", "summary": "This article provides actual and estimated financial data for Puma Biotechnology Inc (NASDAQ: PBYI), covering its stock performance, analyst forecasts, and various financial metrics. It details the company's current stock price, market capitalization, earnings, revenue, and histo", "url": "https://www.tradingview.com/symbols/NASDAQ-PBYI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:09:30", "published_display": "26 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Inc (PBYI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "Puma Biotechnology Inc (PBYI) currently has a price momentum score of 7.50, ranking 73rd in the Pharmaceuticals industry. The stock is trading between a resistance level of 8.46 and a support level of 6.83, suggesting potential for range-bound swing trading. Technical indicators ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pbyi/technical", "source_name": "TradingKey", "published_at": "2026-06-24T13:41:05", "published_display": "24 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PBYI SEC Filings - Puma Biotechnology Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Puma Biotechnology Inc. (PBYI) SEC filings, including annual 10-K reports, quarterly 10-Q reports, and material 8-K events. These filings offer insights into the company's financials, corporate governance, and oncology programs. The", "url": "https://www.stocktitan.net/sec-filings/PBYI/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-19T13:09:40", "published_display": "19 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Puma Biotechnology Inc (PBYI) currently holds an earnings forecast score of 6.00, placing it 132nd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for PBYI, with an expected revenue of $53.00 million for the next quarter. The consens", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pbyi/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:07", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology stock (US7392761034): Q2 2026 guidance signals revenue expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNalZBSVJHMmlPeXRLaWRiNzZVRGZfNzRrdEl3ajNhMVlxc2JaTk1pZTR1aFN0Q2ZGaWhWUlp4QUVmaFRvNXpqRDZrblVvSFlWcW1MVWNBMWJDUHFSb0VOR0pTbHpuWENSVEZhRTI0NWFDLWRCWC1MMTFPRkRlbTd3T1czRWtDZENVblE2azBtUk15NDMzWlJEOUhxa3BHNjFXeG45Z0J4VnZiUkZDQ3lyS3RNWDBSN2pDNDVxS3VQU0JfX1hlUV9hVg?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUTY4SzBROHBQYlRIT2Y0U2NWN1NHN0hlSkJHNXZMamhvN1dpRWVpNlZKb3I4UDAtOVZRS2dqNzRiTWZISUtTdlZVbldnZ3pfV1N0VXh0NWV0ckpMcUZGRDdaZGlXSEFZWktvdHVreUladmplcUJXLUpMYUxpMVBIOEJWSlJodnJhZjBHMlN6dF8zVUlRWHlHblFQZ3dNa1FWUDJ4eVVNMWVZZ0dVaWtsZEhBcTB2bFNROXE3VXFYQ3NJWXIxYjRYZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTXNUdVZadGlGUFRyY004aWwyQUQ1eUhVLVRxbUJtWTVrSndNdFV0S0xJYjdPTlhUVmNxVDl3Q2Y4VnE0d280bDh3QlFOOUNHS2JtRExnX0FfWHozeUNKVDhpRjJLbHZjdHdEQ0hldlRZbTFKdVNqWFEzRlFCbkNOclYweTJCcnNvXzFXWWVRWEhnSXVPbVJwSUJSbldKQlFXUF8zOTdKYlRxUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/add18b6a-d07b-39c7-af97-f2b3f409843b/puma-biotechnology-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-08T19:12:28+00:00", "published_display": "08 May 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/e1a94306-ade8-3e9d-848d-ef6fabdb40e7/puma-biotechnology%2C-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-08T12:30:00+00:00", "published_display": "08 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOTlBxUW9QV2o3YTF4RVdzWWlWUWZfU2V6Y25mcHBxM2RQTkpES0FqY0xsRDdtc0NqZE1KY2RFSWFfMGVCSVR2RXpndERPOFF6al9HQndCU2p0SkpPQ3dsc19BaVVvSzFxQ2FwcGEwVFlxNUFmZUUtdHpvVmpfQkFDX2FVLXprUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] PUMA BIOTECHNOLOGY, INC. SEC Filing", "summary": "This article details a PUMA BIOTECHNOLOGY, INC. SEC Filing of Form 144, indicating a proposed sale of securities. The filing shows that 9,386 shares of common stock, valued at $77,554.64, are to be sold through Fidelity Brokerage Services LLC, originating from restricted stock ve", "url": "https://www.stocktitan.net/sec-filings/PBYI/144-puma-biotechnology-inc-sec-filing-d232b7e2cfcb.html", "source_name": "Stock Titan", "published_at": "2026-07-09T09:11:39", "published_display": "09 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Puma Biotechnology Inc For: 8 July By Investing.com", "summary": "This article reports on a Form 4 filing for Puma Biotechnology Inc. dated July 8. Form 4s disclose transactions by insiders, but the article does not provide specific details from the filing. It briefly mentions Puma Biotechnology Inc. (PBYI) and its current stock performance.", "url": "https://ca.investing.com/news/stock-market-news/form-4-puma-biotechnology-inc-for-8-july-93CH-4726292", "source_name": "Investing.com Canada", "published_at": "2026-07-09T07:10:19", "published_display": "09 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology\u2019s Douglas M. Hunt sells $69,904 in shares", "summary": "Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 8,460 shares of the company's stock for $69,904. This transaction took place as part of a pre-arranged plan, with the stock trading near its 52-week high after a significant gain. Despite thi", "url": "https://www.investing.com/news/insider-trading-news/puma-biotechnologys-douglas-m-hunt-sells-69904-in-shares-93CH-4782864", "source_name": "Investing.com", "published_at": "2026-07-09T07:10:19", "published_display": "09 Jul 2026 07:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma biotechnology CFO Maximo Nougues sells $77,556 in stock", "summary": "Maximo F. Nougues, CFO of Puma Biotechnology, Inc. (NASDAQ:PBYI), sold 9,386 shares of company stock for $77,556 on July 6, 2026. This transaction was part of a pre-established sell-to-cover program, leaving Nougues with 230,637 shares. The sale occurred while PBYI stock was near", "url": "https://www.investing.com/news/insider-trading-news/puma-biotechnology-cfo-maximo-nougues-sells-77556-in-stock-93CH-4782856", "source_name": "Investing.com", "published_at": "2026-07-09T07:10:19", "published_display": "09 Jul 2026 07:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 By Investing.com", "summary": "Alan Auerbach, President and CEO of Puma Biotechnology (NASDAQ:PBYI), sold 44,058 shares of company stock for $364,051 on July 6, 2026, under a pre-established trading plan. This sale occurred while the stock was near its 52-week high, having gained 126% in the past year, though ", "url": "https://ng.investing.com/news/stock-market-news/alan-auerbach-puma-biotechnology-president-and-ceo-sells-364051-93CH-2592089", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T01:30:00", "published_display": "09 Jul 2026 01:30", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PUMA Biotechnology (PBYI) officer Douglas Hunt sells 8,460 shares under 10b5-1 plan", "summary": "Douglas M. Hunt, an officer at PUMA Biotechnology (PBYI), reported an open-market sale of 8,460 shares of company stock at an average price of $8.263 per share. This transaction was conducted under a Rule 10b5-1(c) sell-to-cover plan established on December 14, 2020. Following th", "url": "https://www.stocktitan.net/sec-filings/PBYI/form-4-puma-biotechnology-inc-insider-trading-activity-a4829d1521b0.html", "source_name": "Stock Titan", "published_at": "2026-07-09T00:43:37", "published_display": "09 Jul 2026 00:43", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology (PBYI) CFO sells 9,386 shares in 10b5-1 trade", "summary": "Puma Biotechnology's CFO, Maximo F. Nougues, sold 9,386 shares of common stock on July 6, 2026, for $8.263 per share, totaling approximately $78,000. This transaction was conducted under a pre-arranged Rule 10b5-1(c) sell-to-cover plan established in December 2020. After the sale", "url": "https://www.stocktitan.net/sec-filings/PBYI/form-4-puma-biotechnology-inc-insider-trading-activity-9702a28e772a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T23:43:38", "published_display": "08 Jul 2026 23:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology (PBYI) CEO sells 44,058 shares under 10b5-1 plan", "summary": "Puma Biotechnology's President and CEO, Alan H. Auerbach, sold 44,058 shares of common stock at $8.263 per share on July 6, 2026. This transaction was conducted under a pre-established Rule 10b5-1(c) sell-to-cover program adopted in December 2020. Following the sale, Auerbach sti", "url": "https://www.stocktitan.net/sec-filings/PBYI/form-4-puma-biotechnology-inc-insider-trading-activity-8c9b981062db.html", "source_name": "Stock Titan", "published_at": "2026-07-08T00:43:38", "published_display": "08 Jul 2026 00:43", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PUMA BIOTECHNOLOGY, INC. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Puma Biotechnology, Inc. (PBYI), indicating a proposed sale of securities under Rule 144. The filing details the acquisition of 44,058 shares through restricted stock vesting on July 1, 2026, and their intended sale on July 6, 2026", "url": "https://www.stocktitan.net/sec-filings/PBYI/144-puma-biotechnology-inc-sec-filing-056ca4797df4.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:40:22", "published_display": "06 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PBYI - Puma Biotechnology Inc Latest SEC Filings", "summary": "This article provides comprehensive financial data and performance metrics for Puma Biotechnology Inc (PBYI), including its latest stock close, market capitalization, income, sales, and various ratios. It also details insider and institutional ownership, analyst recommendations, ", "url": "https://finviz.com/stock?t=PBYI&b=2&p=d&ty=lf&page=5", "source_name": "Finviz", "published_at": "2026-07-04T18:09:31", "published_display": "04 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Puma Biotechnology Inc \u2013 NASDAQ:PBYI", "summary": "The article provides a snapshot of Puma Biotechnology Inc. (NASDAQ: PBYI) on TradingView, focusing on its \"Price to sales forward\" metric. It indicates that the market was closed at the time of viewing, with no trades, and offers various data points like financials, news, and tec", "url": "https://www.tradingview.com/symbols/NASDAQ-PBYI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T13:40:43", "published_display": "04 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology highlights targeted cancer therapies as investors watch Nasdaq-listed PBYI", "summary": "Puma Biotechnology is a Nasdaq-listed biopharmaceutical company focusing on targeted oncology therapies, particularly for HER2-positive breast cancer. The company's strategy involves commercializing its approved drug while investing in pipeline development for additional indicati", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/puma-biotechnology-highlights-targeted-cancer-therapies-as-investors-watch/69679640", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T12:09:59", "published_display": "03 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology awards stock to four new employees", "summary": "Puma Biotechnology, Inc. announced the grant of 31,625 restricted stock unit awards to four new non-executive employees. These awards are an inducement for new hires and will vest over a three-year period, with the first portion vesting on July 1, 2026, and subsequent portions ev", "url": "https://www.stocktitan.net/news/PBYI/puma-biotechnology-reports-inducement-awards-under-nasdaq-listing-62tusnize1gg.html", "source_name": "Stock Titan", "published_at": "2026-07-03T07:10:09", "published_display": "03 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026", "summary": "Puma Biotechnology (NASDAQ: PBYI) announced inducement restricted stock unit awards covering 31,625 shares to four new non-executive employees, approved by its Compensation Committee on July 1, 2026. These awards, granted under the company's 2017 plan, vest over three years, with", "url": "https://www.biospace.com/press-releases/puma-biotechnology-reports-inducement-awards-under-nasdaq-listing-rule-5635c4-july-2-2026", "source_name": "BioSpace", "published_at": "2026-07-03T04:09:06", "published_display": "03 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PBYI News | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFBLUFNLOF9wV3hhSGtaQ3QzeDllNEZpQlVOV29QZk1qX3FleGRmTy1UNXlvVnpWRDJBWnZvTlNmWlo5a1JjcVFjdk5BelhadGo4ZDJsZFJJVXpwNGc?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:02+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNOXEyZVlzMUpOenRqNVF2Tm8tdnJSa2luenExck1VM21XSnh0NHVSVFI0VDc1ejRVWnZqS0ZVMjNHNmFvT1JhNEoyX0lqMkVyUFMwTWJUWmV3ZlI4SFE5OFFjYVdvWUo0c19DNVRYYks2UW1PTFEzWGlaMW8yWlN3LU5oZ3JZaEZMVDk4TWJreTlIUWZzdng2cg?oc=5", "source_name": "Market source", "published_at": "2026-07-02T21:03:00+00:00", "published_display": "02 Jul 2026 21:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Growth Benchmark", "summary": "Puma Biotechnology, Inc. (NasdaqGS:PBYI), a biopharmaceutical company focusing on cancer care, has been added to the Russell Small Cap Comp Growth Benchmark, as well as several other Russell Growth benchmarks on June 29, 2026. This news follows previous announcements earlier in t", "url": "https://www.marketscreener.com/news/puma-biotechnology-inc-nasdaqgs-pbyi-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd8efe22", "source_name": "marketscreener.com", "published_at": "2026-06-30T16:12:19", "published_display": "30 Jun 2026 16:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 2500 Growth Benchmark", "summary": "Puma Biotechnology, Inc. (NasdaqGS: PBYI) has been added to the Russell 2500 Growth Benchmark, as well as several other Russell indices including the Russell Small Cap Comp Growth Benchmark, Russell 2000 Growth Benchmark, and Russell 3000E Growth Benchmark. This news comes shortl", "url": "https://www.marketscreener.com/news/puma-biotechnology-inc-nasdaqgs-pbyi-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f326", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:41:16", "published_display": "29 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 3000E Growth Benchmark", "summary": "Puma Biotechnology, Inc. (PBYI) has been added to the Russell 3000E Growth Benchmark. This news follows a previous announcement that the company was also added to the Russell 2000 Growth Benchmark on the same day. Puma Biotechnology specializes in developing and commercializing p", "url": "https://www.marketscreener.com/news/puma-biotechnology-inc-nasdaqgs-pbyi-added-to-russell-3000e-growth-benchmark-ce7f5fdeda88f720", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:06:00", "published_display": "29 Jun 2026 12:06", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Puma Biotechnology Inc \u2013 BOATS:PBYI", "summary": "This article provides a financial snippet for Puma Biotechnology Inc (PBYI), specifically its enterprise value to revenue forward metric. The content highlights the stock's market status as closed with no recent trades and is presented within the TradingView platform.", "url": "https://www.tradingview.com/symbols/BOATS-PBYI/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:10:24", "published_display": "29 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PBYI Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Puma Biotechnology Inc (PBYI) stock, including analyst price targets and historical performance data. One analyst projects a maximum and minimum price target of $5.00 for PBYI. The stock has shown significant increases over the past year, and ", "url": "https://www.tradingview.com/symbols/NASDAQ-PBYI/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T15:39:45", "published_display": "28 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Puma Biotechnology Inc \u2013 NASDAQ:PBYI", "summary": "This article provides financial information for Puma Biotechnology Inc (NASDAQ: PBYI), specifically its price-to-book forward ratio. It highlights that the market was closed at the time of access and contains no active trades or specific current values. The content appears to be ", "url": "https://www.tradingview.com/symbols/NASDAQ-PBYI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:09:46", "published_display": "28 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Puma Biotechnology Inc \u2013 BOATS:PBYI", "summary": "This article provides financial information for Puma Biotechnology Inc (PBYI), specifically its price to sales forward metric. The content indicates that the market is currently closed with no trades. It also links to various TradingView features and legal information.", "url": "https://www.tradingview.com/symbols/BOATS-PBYI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:40:37", "published_display": "27 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Puma Biotechnology Inc \u2013 BOATS:PBYI", "summary": "This article displays an enterprise value to EBITDA forward metric for Puma Biotechnology Inc (PBYI), as presented by Blue Ocean Alternative Trade System (BOATS) on TradingView. The page primarily showcases financial data with no specific values or analytical commentary provided ", "url": "https://www.tradingview.com/symbols/BOATS-PBYI/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:09:47", "published_display": "27 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. Actuals & Estimates (NASDAQ:PBYI)", "summary": "This article provides actual and estimated financial data for Puma Biotechnology Inc (NASDAQ: PBYI), covering its stock performance, analyst forecasts, and various financial metrics. It details the company's current stock price, market capitalization, earnings, revenue, and histo", "url": "https://www.tradingview.com/symbols/NASDAQ-PBYI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:09:30", "published_display": "26 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Inc (PBYI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "Puma Biotechnology Inc (PBYI) currently has a price momentum score of 7.50, ranking 73rd in the Pharmaceuticals industry. The stock is trading between a resistance level of 8.46 and a support level of 6.83, suggesting potential for range-bound swing trading. Technical indicators ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pbyi/technical", "source_name": "TradingKey", "published_at": "2026-06-24T13:41:05", "published_display": "24 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PBYI SEC Filings - Puma Biotechnology Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Puma Biotechnology Inc. (PBYI) SEC filings, including annual 10-K reports, quarterly 10-Q reports, and material 8-K events. These filings offer insights into the company's financials, corporate governance, and oncology programs. The", "url": "https://www.stocktitan.net/sec-filings/PBYI/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-19T13:09:40", "published_display": "19 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Puma Biotechnology Inc (PBYI) currently holds an earnings forecast score of 6.00, placing it 132nd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for PBYI, with an expected revenue of $53.00 million for the next quarter. The consens", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pbyi/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:07", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology stock (US7392761034): Q2 2026 guidance signals revenue expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNalZBSVJHMmlPeXRLaWRiNzZVRGZfNzRrdEl3ajNhMVlxc2JaTk1pZTR1aFN0Q2ZGaWhWUlp4QUVmaFRvNXpqRDZrblVvSFlWcW1MVWNBMWJDUHFSb0VOR0pTbHpuWENSVEZhRTI0NWFDLWRCWC1MMTFPRkRlbTd3T1czRWtDZENVblE2azBtUk15NDMzWlJEOUhxa3BHNjFXeG45Z0J4VnZiUkZDQ3lyS3RNWDBSN2pDNDVxS3VQU0JfX1hlUV9hVg?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUTY4SzBROHBQYlRIT2Y0U2NWN1NHN0hlSkJHNXZMamhvN1dpRWVpNlZKb3I4UDAtOVZRS2dqNzRiTWZISUtTdlZVbldnZ3pfV1N0VXh0NWV0ckpMcUZGRDdaZGlXSEFZWktvdHVreUladmplcUJXLUpMYUxpMVBIOEJWSlJodnJhZjBHMlN6dF8zVUlRWHlHblFQZ3dNa1FWUDJ4eVVNMWVZZ0dVaWtsZEhBcTB2bFNROXE3VXFYQ3NJWXIxYjRYZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTXNUdVZadGlGUFRyY004aWwyQUQ1eUhVLVRxbUJtWTVrSndNdFV0S0xJYjdPTlhUVmNxVDl3Q2Y4VnE0d280bDh3QlFOOUNHS2JtRExnX0FfWHozeUNKVDhpRjJLbHZjdHdEQ0hldlRZbTFKdVNqWFEzRlFCbkNOclYweTJCcnNvXzFXWWVRWEhnSXVPbVJwSUJSbldKQlFXUF8zOTdKYlRxUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/add18b6a-d07b-39c7-af97-f2b3f409843b/puma-biotechnology-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-08T19:12:28+00:00", "published_display": "08 May 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/e1a94306-ade8-3e9d-848d-ef6fabdb40e7/puma-biotechnology%2C-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-08T12:30:00+00:00", "published_display": "08 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOTlBxUW9QV2o3YTF4RVdzWWlWUWZfU2V6Y25mcHBxM2RQTkpES0FqY0xsRDdtc0NqZE1KY2RFSWFfMGVCSVR2RXpndERPOFF6al9HQndCU2p0SkpPQ3dsc19BaVVvSzFxQ2FwcGEwVFlxNUFmZUUtdHpvVmpfQkFDX2FVLXprUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 82, "total_relevant": 48, "sentiment_summary": {"positive": 9, "negative": 8, "neutral": 31, "score": 51, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 13.75, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 10.45, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 8.0, "latest_week": "2026-07-10", "one_week_move": -3.1, "four_week_move": 9.1, "twelve_week_move": 7.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.831478, "market_dynamics_buy_signal": false, "relative_strength": 15.554959, "fair_value_gap": 82.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.9481, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.1% over one week, +9.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 9}, {"label": "Stock Titan", "count": 7}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "www.marketscreener.com", "count": 2}, {"label": "TradingKey", "count": 2}, {"label": "Investing.com Canada", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.1% over one week, +9.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks"}], "updated_at": "2026-07-16T11:51:20.219425+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}